Malgorzata Bobrowicz

List of Publications by Year
in descending order

24 papers	360 citations	840776 11 h-index	839539 18 g-index
24 all docs	24 docs citations	24 times ranked	735 citing authors

#	Article	IF	Citations
1	Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy. International Journal of Molecular Sciences, 2018, 19, 2256.	4.1	63
2	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	1.4	40
3	Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020. International Archives of Allergy and Immunology, 2020, 181, 733-745.	2.1	35
4	Blockade of programmed cell death protein 1 (PD-1) in SÃ©zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology, 2020, 9, 1738797.	4.6	32
5	Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate. Redox Biology, 2019, 21, 101062.	9.0	29
6	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. OncoImmunology, 2018, 7, e1423183.	4.6	23
7	Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in SÃ©zary syndrome. Leukemia and Lymphoma, 2019, 60, 1899-1907.	1.3	23
8	B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases, 2015, 55, 255-265.	1.4	22
9	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	5.2	16
10	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146, 173-183.	4.4	16
11	CD37 in B Cell Derived Tumorsâ€”More than Just a Docking Point for Monoclonal Antibodies. International Journal of Molecular Sciences, 2020, 21, 9531.	4.1	16
12	Molecular Aspects of Resistance to Immunotherapiesâ€”Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences, 2022, 23, 1501.	4.1	13
13	Monoclonal Antibodies in Dermatooncologyâ€”State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	3.7	9
14	Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in SÃ©zary syndrome. OncoImmunology, 2021, 10, 1873530.	4.6	6
15	Selective inhibition of HDAC6 sensitizes cutaneous Tâ€cell lymphoma to PI3K inhibitors. Oncology Letters, 2020, 20, 533-540.	1.8	6
16	The â€œMagic Bulletâ€•Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells, 2021, 10, 1511.	4.1	3
17	Lysosomal Disruption Augments Obinutuzumab-Induced Direct Cell Death. Blood, 2016, 128, 2766-2766.	1.4	3
18	SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL. Blood, 2018, 132, 2860-2860.	1.4	2

#	Article	IF	Citations
19	Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter. Blood, 2013, 122, 1838-1838.	1.4	1
20	HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4406-4406.	1.4	1
21	Influence of Btk Inhibitors on Antitumor Activity of Natural Killer Cells. Blood, 2014, 124, 2742-2742.	1.4	1
22	Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies. Blood, 2013, 122, 4217-4217.	1.4	0
23	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. Blood, 2014, 124, 3641-3641.	1.4	0
24	HDAC6 Inhibition Increases Translation of CD20 mRNA and Potentiates the Efficacy of Anti-CD20 Immunotherapy. Blood, 2016, 128, 1586-1586.	1.4	0